Foam Sclerotherapy for Cyst Volume Reduction in Autosomal Dominant Polycystic Kidney Disease: A Prospective Cohort Study

• Published in: Kidney medicine 2019-11, Vol.1 (6), p.366-375
• Main Authors: Iliuta, Ioan-Andrei, Shi, Beili, Pourafkari, Marina, Akbari, Pedram, Bruni, Giancarlo, Hsiao, Ralph, Stella, Steffan F., Khalili, Korosh, Shlomovitz, Eran, Pei, York
• Format: Article
• Language: English
• Subjects: autosomal dominant polycystic kidney disease; cyst ablation; Foam sclerotherapy; kidney volume reduction; Original Research
• ISSN: 2590-0595; 2590-0595
• DOI: 10.1016/j.xkme.2019.07.015

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder. Progressive increase in cyst number and size leads to kidney failure in a majority of patients. Large kidney cysts, although few, can be especially deleterious by impeding kidney blood flow and obstructing urine flow over a large region. Foam sclerotherapy is a minimally invasive procedure that may be used to ablate large cysts. We examined the effectiveness and safety of foam sclerotherapy for kidney volume reduction in patients with ADPKD. Prospective cohort study. Adults with ADPKD at a tertiary referral center in Toronto. Foam sclerotherapy. Volume of treated kidneys and adverse events. Treated and nontreated kidney volume, kidney function, tolerability, and symptoms were analyzed within each patient. We performed 77 foam sclerotherapy treatment sessions in 66 patients. Foam sclerotherapy was associated with a 21.8% volume reduction of the treated kidneys (n=95; median, 1,138 [IQR, 801-1,582] mL before vs 891 [IQR, 548-1,450] mL after; P